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The ERBB2 gene is overexpressed in 30% of breast cancers and this has been correlated with poor prognosis. ERBB2 is upregulated
in other cancers such as prostate, pancreas, colon and ovary. In breast cancer cells, the mechanisms leading to ERBB2 gene
overexpression are increased transcription and gene amplification. In these cancers, AP-2 transcription factors are involved in ERBB2
overexpression, and AP-2 levels are correlated with p185
c-erbB-2 levels. In this work, we wanted to know if the same molecular
mechanisms are responsible for the ERBB2 upregulation in non-breast cancers. We compared ERBB2 gene copy number, p185
c-erbB-2
and mRNA levels with AP-2 levels in several ovary, prostate, colon and pancreas cancer cells. A moderate expression of erbB-2
mRNA and protein were observed in some cells without gene amplification. In contrast to breast cancer cells, AP-2 factors were
absent or low in some non-breast cells which did express ERBB2. It is thus likely that AP-2 is not a major player in the increased levels
of erbB-2 transcripts in non-breast cancer cells. The transcriptional activity of the ERBB2 promoter in colon and ovary cancer cells was
estimated using reporter vectors. The results showed that the promoter regions involved in ERBB2 gene overexpression in breast
cancer cells are different from those that lead to the gene upregulation in colon and ovary cancers. In conclusion, our results indicate
that different transcriptional and post-transcriptional mechanisms are responsible for the increased levels of erbB-2 transcript and
protein in breast and non-breast cancer cells.
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The ERBB2 gene is located on chromosome 17q21 and encodes a
185kDa transmembrane receptor (p185
c-erbB-2) belonging to the
EGFR family (Yarden and Sliwkowski, 2001). ERBB2 is over-
expressed in about 30% of breast and ovary cancers and this has
been correlated with poor prognosis for the patient (Ross and
Fletcher, 1999). Recently, the use of a p185
c-erbB-2 targeted
antibody, trastuzumab (Herceptin), has been used successfully to
inhibit the growth of breast cancer cells.
Most of the studies aimed at understanding the molecular basis
of ERBB2 overexpression have been performed in breast cancers.
In these cancers, the molecular mechanisms involved are
transcriptional upregulation and gene amplification (Hollywood
and Hurst, 1993; Pasleau et al, 1993). AP-2 and Ets family
transcription factors have been shown to contribute to ERBB2
overexpression in breast cancer cells. The AP-2 transcription
factors upregulate the ERBB2 expression by binding to two
sites located  213bp (Bosher et al, 1996) and  500bp
upstream the Cap site (Vernimmen et al, 2003). The Ets
transcription factor stimulates ERBB2 expression by preventing
the formation of a triplex structure on the core promoter (Scott
et al, 2000).
The ERBB2 gene is also overexpressed in other cancers such as
prostate, colon and pancreas cancers, and this alteration has also
been considered as a negative prognosis marker by some authors
(Klapper et al, 2000).
In this report, we address, for the first time, the molecular
mechanisms leading to ERBB2 gene overexpression in non-breast
cancer cells. We wanted to know if the mechanisms, which have
been shown to operate in breast cancers, are also at work in non-
breast cancers. For this purpose, we used cell lines derived from
ovary, prostate, colon, liver and pancreas cancers. First, we
compared the ERBB2 gene copy number, mRNA and protein
levels. The p185
c-erbB-2 levels were estimated by immunocytochem-
istry (ICC) and Western blotting. The ERBB2 gene copy numbers
and mRNA levels were measured by real-time PCR. In parallel, we
assessed the AP-2 levels and DNA binding activities in all these cell
lines. The results showed a moderate ERBB2 overexpression in a
significant proportion of non-breast cancer cells. Contrary to the
results obtained in breast cancer cell lines, there was no correlation
between the levels of the erbB-2 mRNA and the AP-2 transcription
factor. We then analysed the ERBB2 promoter activity in the
different cell lines by transfecting reporter vectors containing
progressive deletions of a 6kb promoter (Grooteclaes et al, 1994).
The transcriptional activity increased with increasing sizes of the
ERBB2 promoter. Nevertheless, the regulatory fragments we
identified in breast cancer cells (Grooteclaes et al, 1994) function
differently in non-breast cancer cells. In conclusion, the accumula-
tion of erbB-2 mRNA and protein in breast and non-breast cancer
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MATERIAL AND METHODS
Cell lines
The mammary (BT-474, ZR-75.1 and MDA-MB-231), hepatic
(HepG2), prostatic (LNCaP, DU 145 and PC-3), colon (WiDr,
HTm29, HCT 116, COLO 205 and COLO 320), ovary (OVCAR-3
and SK-OV-3) and pancreatic (PANC-1, Miapaca-2, HS766T, CF-
PAC-1, SU.86.86, BxPC-3 and Capan-2) human epithelial cells were
purchased from American Type Culture Collection (Manassas, VA,
USA) and cultured in the recommended media supplemented with
10% fetal bovine serum, 2mM glutamine and 100mgml
 1
penicillin/streptomycin. (Biowhittaker, Walkersville, MD, USA).
Immunocytochemistry
Cells (50 10
6) were harvested by trypsinisation and centrifuga-
tion. After centrifugation, the cell pellets were fixed in 2%
paraformaldehyde (UCB, Louvain, Belgium), then embedded
in paraffin. Sections (5mm thick) were deparaffinized and
rehydrated using xylene and graded alcohols. The sections were
heated at 1001C for 40min in a citrate buffer, then incubated
for 20min at room temperature. Endogenous peroxidase
activity was blocked with 5% H2O2 for 5min. After two washes,
for 5min each, with 1% tween-phosphate-buffered saline
(PBS) solution, the sections were incubated with an antibody
diluent solution (Dako Diagnostics, Glostrup, Denmark) contain-
ing a c-erbB-2 monoclonal antibody (1:300) raised against
the internal domain of the p185
c-erbB-2 protein (NCL-CB11,
Novocastra, Newcastle, UK). Anti-mouse HRP-labelled polymer
(Dako) was applied for 30min at room temperature and the slides
were washed for 2 5min with 1% tween-PBS solution. The
sections were then incubated for 40min with DAB
þ substrate
(Dako), washed three to four times in water and counterstained
with haematoxylin. Cytoplasmic and membrane immunostaining
was evaluated using a 0 to 3þ scale (0, negative or equivocal
positivity; 1þ, weak positivity; 2þ moderate positivity; 3þ
strong positivity).
Real-time PCR and real-time RT–PCR
Genomic DNA was extracted by the phenol–chloroform procedure
(Maniatis et al, 1982). Total cellular RNA was extracted with the
Tripure Isolation Reagent (Roche Diagnostic, Basel, Switzerland).
DNA and RNA quantification were performed with the Light-
Cycler–HER2/neu DNA and RNA Quantification Kits (Roche).
Electromobility shift assays (EMSA)
Nuclear extracts, HTF/AP-2 cis sequence and EMSA were
described elsewhere (Schreiber et al, 1989; Vernimmen et al,
2003). Briefly, 2–4mg of crude nuclear proteins were incubated
with 300000c.p.m. of [a-
32P]dCTP end-labelled oligonucleotide.
The retarded complexes were analysed on a nondenaturing 5%
polyacrylamide gel and analysed using a PhosphorImager
(Molecular Dynamics Amersham Biosciences, Roosendal, The
Netherlands).
Western blotting
For p185
c-erbB-2 detection, cells were scraped off the culture
dishes, harvested in PBS, pelleted by centrifugation, resuspended
in a 1% SDS solution and boiled for 10min. Whole cell
extracts (20mg) were loaded per well, separated on a 12%
SDS–polyacrylamide gel and transferred to a PVDF membrane
(Millipore, Brussels, Belgium). A c-erbB-2 antibody (06-562
Euromedex, Mundolsheim, France) was used at a 1:2000 dilution.
For AP-2 detection, 10–25mg of nuclear extracts were loaded
per well. An AP-2a antibody (sc-184 Santa Cruz Biotechnology,
Santa Cruz, CA, USA) was used at a 1:700 dilution. Secondary
antibodies (Dako Diagnostics, Glostrup, Denmark) were
detected with the ECL system (Amersham BioSciences). The
b-actin monoclonal antibody was from Sigma (monoclonal
(amoeba) mouse ascites fluid clone KJ43A Sigma-Aldrich Bernem,
Belgium).
Plasmids and transient transfection assays
The transfection efficiencies of all the cell lines were tested by
transfection of the pEGFP-IRESpuro control vector (Clontech, Palo
Alto, CA, USA). Cells were transfected using the FuGENE 6 reagent
(Roche). Cells (4 10
5) were plated on 35mm tissue culture dishes
with a FuGENE/DNA ratio of 3:1. The cells were incubated for 48h
in complete medium. Cells transfected with the green fluorescent
protein (GFP) expression plasmid were visualised by fluorescent
microscopy. The luciferase (LUC) reporter vectors containing
different ERBB2 promoter fragments have been previously
described (Grooteclaes et al, 1994). The LUC enzymatic activities
were measured using the Luciferase Reporter Gene Assay kit
(Roche).
RESULTS
ErbB-2 gene copy number, mRNA and protein levels in
cancer cell lines
We measured the p185
c-erbB-2 protein levels by ICC and Western
blotting. For ICC, we used the well characterised breast cancer cell
lines BT-474 and ZR-75-1 as standards to determine the erbB2
expression in the non-breast cells (Figure 1A, C). After ICC,
p185
c-erbB-2 appeared as a brown membrane staining in positive
breast cancer cells. Likewise, p185
c-erbB-2 exhibited an intense
membranous staining in SK-OV-3 ovary carcinoma cells
(Figure 1B). P185
c-erbB-2 was detected in one out of two ovary,
four out of five colorectal, three out of three prostatic and only two
out of seven pancreatic cancer cells, but the staining was
heterogeneous and mainly cytoplasmic (Figure 1D and Table 1).
P185
c-erbB-2 was also detected in the cytoplasm of HepG2
hepatocarcinoma cells (Figure 1E). Figure 1F presents a pancreatic
cell line negative for p185
c-erbB-2.
The p185
c-erbB-2 levels were also estimated by Western blotting
of whole-cell extracts (Table 1 and Figure 4). As cell density
has been reported to modulate p185
c-erbB-2 levels in breast cancer
cells (Kornilova et al, 1992), we compared the oncoprotein levels
in low (50% confluence)- and high (100% confluence)-density
cultures. The full-length, 185kDa protein, was detected in most
analysed cells. A slight difference was observed between low-
and high-density cultures of breast, ovary and pancreatic cell
lines (Figure 4). The highest p185
c-erbB-2 levels were observed
in BT-474 breast and SK-OV-3 ovary cancer cells (Table 1). In
order to compare the protein content between the different
cancer types, we attributed the value of one to the p185
c-erbB-2
measured in MDA-MB-231 mammary cancer cells (Table 1).
BT-474 and SK-OV-3 cells contained the highest protein
levels associated with gene amplification and mRNA overexpres-
sion. Among the cells without gene amplification, HepG2
hepatocarcinoma and LNCaP prostate cancer cells were most
enriched in p185
c-erbB-2. All the colon cancer cell lines contained
almost similar protein levels not significantly different from
that of MDA-MB-231 cells. The pancreatic cell lines SU.86.86,
BxPC-3, HS766T and PANC-1 contained very low levels of
p185
c-erbB-2, detectable only after long exposure time. Only
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exceeded the MDA-MB-231 p185
c-erbB-2 levels. Notice the wide
variation in p185
c-erbB-2 between the pancreatic cancer cells. In
general, Western blotting and ICC results were in reasonably good
agreement (Table 1).
The erbB-2 mRNA levels were measured by real-time RT–PCR.
The results are summarised in Table 1 and compared to the
Western blotting data. In most cells, real-time RT–PCR and
Western blotting data were in good agreement, except for the
COLO 320 cancer cells. Indeed, in these cells, the increase in
transcript levels was not accompanied by an increase in protein
levels (Table 1). Like the protein levels, erbB-2 mRNA levels were
quite high in HepG2 cells.
The ERBB2 gene copy numbers were estimated by real-time
PCR in all cancer cells (Table 1). The gene was not amplified
in any of the prostate, colon and pancreatic cancer cells.
SK-OV-3 presents a four-fold amplification of the ERBB2
gene.
Figure 1 Representative examples of p185
c-erbB-2 immunostaining in
cancer cell lines. (A) BT-474 (mammary cell line with ERBB2 amplification
and 3þ membrane overexpression). (B) SK-OV-3 (ovary cell line with
ERBB2 amplification and 3þ membrane overexpression). (C) ZR-75.1
(mammary cell line without ERBB2 amplification and 2þ membrane
overexpression). (D) HTm29 (colon cell line without ERBB2 amplification
and 2þ cytoplasmic/1þ membrane overexpression). (E) HepG2 (liver
cell line without ERBB2 amplification and 2þ cytoplasmic overexpression).
(F) SU.86.86 (pancreatic cell line without ERBB2 amplification and no
cytoplasmic/membrane expression)(magnification X400).
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overexpression in non-breast cancer cells
AP-2 levels are high in most breast cancer cells overexpressing
ERBB2 (Bosher et al, 1996). To find out if these transcription
factors are also involved in the stimulation of ERBB2 expression
in non-breast cancer cells, we compared AP-2 and erbB-2 levels
in the cell lines used in this study. AP-2a levels were estimated
by Western blotting (Figure 2A) and AP-2 DNA binding activity
was analysed by gel retardation experiments (EMSA) (Figure 2B).
BT-474 and ZR-75.1 breast cancer cells were used as AP-2-positive
controls and HepG2 hepatocarcinoma cells and MDA-MB-231
breast cancer cells as AP-2-negative controls (Bosher et al, 1996).
AP-2 levels were very low in colon cancer cells (Figure 2A, lanes
8–12). Interestingly, in COLO 205 cells, the AP-2 antibody
revealed three intense bands of lower molecular weight
(Figure 2A, lane 11). No DNA binding activity was detected
in these cells (Figure 2B, lane 11), suggesting that this might be
a false positive signal. Low levels of the 50kDa AP-2 factor
were detected in prostate cancer cells (Figure 2A, lanes 5–7). In
the two ovary cancer cell lines, AP-2a was easily detected
(Figure 2A, lanes 13, 14). However, the signal was much less
intense than in breast cancer cells overexpressing AP-2 (see
for instance Figure 2A, lanes 1 and 3). Finally, in the pancreatic
cells, the AP-2a levels were low to moderate. In these cells,
a higher molecular weight band was detected together with
the 50kDa protein (Figure 2A, lanes 15–21). The Western blotting
and the EMSA results showed comparable patterns in all the
cell lines, indicating that when AP-2 was present, it binds
efficiently to DNA.
In conclusion, there was no correlation between AP-2 and erbB-
2 mRNA or protein levels in the non-breast cancer cell lines. The
most striking discrepancy was observed with HepG2 cells, widely
used as AP-2 negative controls, but these cells do express the erbB-
2 mRNA and protein. Our results thus suggest that the AP-2 is not
involved in ERBB2 overexpression in the non-breast cancer cell
lines we tested.
ERBB2 promoter activity in non-breast cancer cells
In order to better understand the mechanisms leading to ERBB2
overexpression in the non-breast cancer cells, we transfected
reporter vectors containing progressive deletions of a 6kb
promoter fragment (Figure 3A). We have shown previously that
these promoter fragments are active in breast cancer cells
(Grooteclaes et al, 1994). The transfection efficiencies of all the
cell lines were estimated by transfection of an EGFP-expression
vector (data not shown). Only the cells having a transfection
efficiency of at least 5%, namely colon and ovary cancer cells, were
used for further studies. The luciferase activity was compared in
cell lines synthesising low vs high levels of the erbB-2 transcript
(HCT 116 vs COLO 320; OVCAR-3 vs SK-OV-3). In both colorectal
cell lines (HCT116 and COLO 320), the 6kb promoter fragment
induced a 2.5-fold increase of the LUC activity compared to the
vector containing 200bp of the promoter (Figure 3B, lane 4 and
3C, lane 4). The low-ERBB2-expressing ovary cancer cells,
OVCAR-3, showed an increase of the LUC activity with the
promoter size (Figure 3D). This increase was similar to that
observed in the colorectal cells (compare Figure 3B–D). Only
the p756-LUC construct increased the LUC activity in ERBB2-
overexpressing SK-OV-3 cells (Figure 3E, lane 2). The longer
promoter fragments downregulated the transcriptional activity to
the basal value (Figure 3E, lanes 3 and 4). It is interesting to note
that in this cell line the ERBB2 gene is amplified four-fold and
overexpressed more than 60 times (King et al, 1992 and personal
results, Table 1).
DISCUSSION
Around 30% of breast cancers overexpress the ERBB2 gene
and this is correlated with a poor prognosis. Besides gene
amplification, several investigators have described the involve-
ment of ETS family (Scott et al, 2000) and AP-2 family (Bates
and Hurst, 1997) transcription factors in the gene overex-
pression. ERBB2 overexpression has also been reported in
cancers of colon (Nakae et al, 1993; Kapitanovic et al, 1994;
Maurer et al, 1998), prostate (Ross et al, 1993; Morote et al, 1999),
ovary (Fajac et al, 1995) and pancreatic (Yamanaka et al, 1993)
origin. However, the mechanisms leading to increased expression
of the gene have not been investigated in these tumours.
Gene amplification is rare in these tumours and cannot account
for the observed increase in the mRNA or protein levels. To
our knowledge, this is the first attempt to understand the
molecular mechanisms leading to ERBB2 overexpression in non-
breast cancers.
First, we assessed p185
c-erbB-2 levels by ICC and by Western
blotting. One of the main observations of this study is that breast
and ovary cancer cell lines were characterised by a membrane
homogeneous staining, whereas in the non-breast cancer cells, the
staining was cytoplasmic and heterogeneous (Figure 1, Table 1).
Several truncated intracellular p185
c-erbB-2 fragments have been
described (Scott et al, 1993; Esparis-Ongando et al, 1999;
Christianson et al, 1998; Molina et al, 2002). These fragments,
which signal actively, might be responsible for the cytoplasmic
staining observed in most non-breast cancer cells. However, only
the full-length protein was detected by Western blotting in these
cells, which does not support the hypothesis that ICC detects a
truncated cytoplasmic protein. The cytoplasmic staining of
p185
c-erbB-2 has already been reported in prostate cancers
(Rosset et al, 1993). De Potter et al (1989) have described
the presence of a protein on the mitochondrial membrane,
appearing as granular staining in the cytoplasm. The significance
of the cytoplasmic staining in breast cancer cells is controversial,
since some authors did not observe a correlation between the
cytoplasmic protein and the mRNA levels (DiGiovanna, 1999; Ross
and Fletcher, 1999). However, in the non-breast cancer cells we
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Figure 2 Distribution of AP-2 transcription factor in non-breast cancer
cell lines. (A) Western blot with10mg (control, lanes 1 and 3) or 20mg
(lanes 2 and 4–21) of crude nuclear extracts from breast and non-breast
cells. The arrowhead marks the 50kDa molecular weight of AP-2
proteins. (B) EMSA assays with 2mg (lanes 1 and 3) or 4mg (lanes 2 and
4–21) of crude nuclear extracts. The arrowhead marks specific AP-2/DNA
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yhave analysed, there was a good correlation between these
parameters. The mechanism by which p185
c-erbB-2 is mainly
cytoplasmic is unknown. The protein might not be properly
targeted to the membrane or, alternatively, might be internalised
(DiGiovanna, 1999).
We have characterised the ERBB2 gene copy number, mRNA
and protein levels in the tumour cell lines investigated in this
study. Gene amplification was detected only in BT-474, MDA-MB-
453 and SK-OV-3 cell lines, which is in good agreement with
already published data. LNCaP prostate carcinoma cells, three
pancreatic cells (Miapaca-2, Capan-2 and CF-PAC-1) and three
colon cancer cells (HCT116, COLO 205 and COLO 320) showed a
significant increase in erbB-2 mRNA levels without gene amplifi-
cation. Compared with breast cancer cells, the increase in the
transcript levels in these cells was low to moderate. HepG2
hepatocarcinoma cells expressed quite high levels of erbB-2 mRNA
and protein. Indeed, the mRNA level was about the same as in
COLO 320 cells but the protein level was much higher than in
colon cancer cells.
The increased levels of p185
c-erbB-2 have been shown to
affect the biology of the tumour. For instance, increased
p185
c-erbB-2 levels in prostate cancers were associated with
the passage from the androgen-dependent to the hormone-
independent status (Signoretti et al, 2000). ErbB2 might stimulate
the proliferation of colon cancer cells by upregulating COX2
(Mann et al, 2001).
In the ovary, prostate and pancreas cells, a good correlation
was observed between the relative protein and mRNA levels
(Figure 4). On the contrary, in colon cancers, we observed
an increase in mRNA levels while the protein levels were
unchanged. We suggest two explanations for this discrepancy.
First, the messenger RNA translation could be less efficient in
colon cancer cells. Indeed, Child et al (1999) have shown that
the erbB-2 transcript is translated with different efficiencies
in different cell lines. Second, the protein half-life might
be shorter in these cells. Future studies are needed to address
these questions.
As a first approach to the understanding of ERBB2 gene
expression regulation in non-breast cancer cell lines, we compared
ERBB2 expression levels with AP-2a protein levels and with AP-2
DNA binding activity in these cells. As EMSA detects the binding
of AP-a, b and g transcription factors, this technique gives a more
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yaccurate picture of AP-2 transcriptional activity than the Western
blotting. We analysed the possible involvement of AP-2 in the
increased ERBB2 expression, because of the well-characterised role
of this transcription factor in breast cancer cells. Indeed, the
500bp proximal ERBB2 promoter contains two AP-2 binding sites,
which contribute to the gene overexpression. The first site is
located 215bp upstream from the transcription initiation site
(Bosher et al, 1995), whereas the second lies 501bp upstream from
the transcription start site (Grooteclaes et al, 1999; Vernimmen
et al, 2003).
Nuclear AP-2a levels and AP-2 DNA binding activities were
considerably lower in prostate, colon, ovary and pancreatic cell
lines than in breast cancer cells. Since AP-2 could be cytoplasmic
rather than nuclear (see below), we also analysed whole-cell
extracts by Western blotting. We did not observe any difference
between nuclear and total AP-2 levels, indicating that the low levels
of the nuclear factor is not the consequence of its cytoplasmic
retention (data not shown). Besides the full-length 50kDa protein,
we detected lower and higher molecular weight proteins as well.
The lower molecular weight bands might result from the
proteolysis of the transcription factor. Higher molecular weight
immunoreactive forms were observed mainly in the pancreatic
cells (Figure 2A) and might represent the recently described,
60kDa sumolated form of the protein. The transcriptional
activity of these sumolated factors is reduced (Eloranta and
Hurst, 2002).
AP-2a levels were not correlated with ERBB2 expression in non-
breast cancer cell lines. This indicates that AP-2 is not involved in
ERBB2 gene overexpression. In other cancers, the role of AP-2 has
been shown to vary according to the tumour type. Some authors
described the loss of AP-2a expression early in the development of
prostate adenocarcinoma (Ruiz et al, 2001). Moreover, AP-2B, a
dominant-negative variant of AP-2a, was detected by RT–PCR in
LNCaP cells (Buettner et al, 1993). Others did detect AP-2a by
immunohistochemistry in some prostate cancer specimens (Lip-
ponen et al, 2000). In primary colorectal (Ropponen et al, 2001)
and ovarian cancers (Anttila et al, 2000), AP-2a was detected in the
nucleus or the cytoplasm of tumour cells. However, the presence of
the transcription factor in the cytoplasm precludes its function in
transcription. Interestingly, high AP-2a mRNA levels were detected
in some tumours which were negative for the protein (Karjalainen
et al, 2000).
To analyse the molecular mechanisms leading to ERBB2
overexpression in non-breast cancer cell lines, we transfected four
LUCIFERASE reporter vectors containing 200bp–6kb fragments
of the ERBB2 promoter in colon and ovary cell lines. The relative
transcriptional activity of each reporter was compared to the
luciferase activity induced by the p255-LUC vector, considered as
equal to one (Grooteclaes et al, 1994). In the colorectal cancer
cell lines, the 700bp fragment induced the same luciferase
activity as the 200bp promoter. The absence of AP-2 in these
cells could explain the result. Indeed, we have shown that
AP-2 is responsible for the transcriptional activating properties
of this fragment in breast cancer cells (Grooteclaes et al, 1999;
Vernimmen et al, 2003). The 6kb promoter fragment induced
a comparable increase in transcriptional activity in both
colorectal cell lines. The three-fold difference in erbB-2 mRNA
levels between HCT116 and COLO 320 cells is probably too small
to be reflected by a significant difference in the promoter activity
(Table 1). In SK-OV-3 ovary cancer cell line, overexpressing about
60 times the erbB-2 transcript, only the p756-LUC vector induced a
significant increase in the transcription level (Figure 3E,
compare lanes 1 and 2). The longer promoter fragments repressed
the transcription. On the contrary, in OVCAR-3 cells, which do
not overexpress ERBB2, we observed a progressive increase in
transcriptional activity with longer promoter fragments. This
result could be explained by the presence of a 8kb transcript with
an extended half-life in SK-OV-3 cells (Doherty et al, 1999a).
Abnormal amounts of the erbB-2 mRNA could accumulate not
only because of transcriptional upregulation, but also because
of its stabilisation. We (Pasleau et al, 1993) and others (Hollywood
and Hurst, 1993; Miller et al, 1994) have shown that mRNA
stabilisation is not responsible for ERBB2 overexpression in breast
cancer cells. However, this is not necessarily true for other
cancers. Another possibility is that other regulatory elements,
located outside the promoter region tested in this study,
could influence ERBB2 expression in colon and ovary cancer
cells. For instance, sequences described in the first intron
(Newman et al, 2000) or 12kb upstream the conventional start
site of the ERBB2 gene (Nezu et al, 1999) should be studied. We
also have to keep in mind the multiple levels of erbB-2 mRNA and
protein expression regulation. Indeed, multiple erbB-2 transcripts
have been described which give rise to different proteins (Scott
et al, 1993; Doherty et al, 1999a,b; Siegel et al, 1999). Moreover,
p185
c-erbB-2 is proteolytically cleaved to generate a soluble
extracellular fragment and a constitutively active intracellular
fragment (Zabrecky et al, 1991; Pupa et al, 1993; Esparis-Ogando
et al, 1999). No single detection method is able to pick up all these
important variants.
In summary, this study is, to our knowledge, the first attempt to
understand the mechanisms of ERBB2 overexpression in non-
breast cancer cells. In these cells, the gene copy number is normal
and the overexpression is moderate. Our results suggest that
different mechanisms lead to ERBB2 overexpression in breast and
in non-breast cancers. In contrast to breast cancer cells, in colon
cancers the protein and transcript levels are not correlated,
suggesting a regulation at the levels of translation and/or post-
translation. One of the main finding is that AP-2 transcription
factors are probably not involved in the increase in erbB-2
transcript levels in tumours of non-breast origins. Fragments of
the ERBB2 promote act differently in breast and in ovary or
colon cancer cells we have analysed. Additional studies are needed
to understand the mechanisms responsible for the increased
accumulation of the erbB-2 transcript and protein in non-breast
cancer cells.
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